Table 6.
Glucagon antagonist peptides for T2DM.
| Peptide Name | AA Sequence | Development Stage | Reference |
|---|---|---|---|
| Native glucagon | HSQGTFTSDYSKYLDSRRAQDFVQWLMNT | N/A | (10) |
| desHis1Glu9-glucagon | SQGTFTSEYSKYLDSRRAQDFVQWLMNT | Preclinical | (344, 345) |
| desHis1Pro4Glu9(Lys12PAL)-glucagon | SQPTFTSEYSK(*PAL)YLDSRRAQDFVQWLMNT | Preclinical | (346, 347) |
| desHis1Pro4Glu9(Lys30PAL)-glucagon | SQPTFTSEYSKYLDSRRAQDFVQWLMNTK(*PAL) | Preclinical | (345, 346, 348) |
| desHis1Glu9-glucagon-[mPEG] | SQGTFTSEYSKYLDSRRAQDFVQWLMNT-[mPEG] | Preclinical | (346) |
Amino acid sequences are provided in their single-letter abbreviation format. Modifications from native sequences are highlighted by red lettering. Current development stages are provided for each. “mPEG” indicates mini-polyethylene glycol addition. “PAL” indicates the addition of a palmitic fatty acid chain.